Notably, CD20 is a major target for monoclonal antibody therapies, such as rituximab, which is widely used in the treatment of B-cell malignancies like follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). The gene discussed is MS4A1; the disease is diffuse large B-cell lymphoma.